Akari Therapeutics plc ADS (NASDAQ: AKTX)
$0.9800
-0.0199 ( +0.41% ) 20.6K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Market Data
Open
$0.9800
Previous close
$0.9999
Volume
20.6K
Market cap
$26.47M
Day range
$0.9750 - $1.0150
52 week range
$0.9000 - $4.4000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Nov 18, 2024 |
| nt | Quarterly Reports | 1 | Nov 15, 2024 |
| 8-k | 8K-related | 15 | Nov 14, 2024 |
| 8-k | 8K-related | 12 | Nov 08, 2024 |
| 4 | Insider transactions | 1 | Nov 01, 2024 |
| 8-k | 8K-related | 11 | Oct 04, 2024 |
| 4 | Insider transactions | 1 | Oct 02, 2024 |
| 8-k | 8K-related | 20 | Sep 18, 2024 |
| 4 | Insider transactions | 2 | Sep 18, 2024 |
| 3 | Insider transactions | 2 | Sep 18, 2024 |